MRC wants to cut the time from bench to bedsideBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39146.416725.BE (Published 08 March 2007) Cite this as: BMJ 2007;334:493
- Michael Day
The UK Medical Research Council (MRC) has signalled an all-out effort to cut the time it currently takes to translate findings of pure research into medical advances.
The MRC's chief executive, Colin Blakemore, announced that it planned to invent, develop, and market its own drugs—with or without industry support—to speed up advances against rare diseases and those that mainly affect developing countries.
He said that the MRC was already holding talks with the Association of the British Pharmaceutical Industry on overhauling “the monolithic clinical trials structure,” which he believes is impeding progress.
His comments came at the launch of the MRC's six new translational medicine centres, which are based at the University of Bristol, the University …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial